PetMed Express Reports Significant Full-Year Loss, Rejects Premium Buyout Offers
PETS sits 35% above its 52-week low of $1.57 on elevated volume (3.0× avg).
Summary
PetMed Express reported a substantial full-year net loss and negative Adjusted EBITDA, but Q4 results showed sequential improvement and beat expectations. The company's Board also rejected unsolicited buyout offers at a significant premium, choosing to remain independent.
Key Events · Earnings and Guidance · PETS
-
Significant Full-Year Financial Decline
For fiscal year 2026, net sales decreased 21.1% to $179.0 million, and the company reported a net loss of $57.3 million (or $(2.74) per share), a substantial worsening from the prior year.
-
Major Goodwill Impairment Charge
The full-year net loss included a significant $26.7 million goodwill impairment charge, highlighting ongoing asset valuation challenges.
-
Q4 Performance Beats Expectations
Fourth-quarter net sales were $42.8 million (down 15.6%), but the net loss of $(0.19) per diluted share was an improvement from the prior year and reportedly better than analyst expectations.
-
Board Rejects Premium Buyout Offers
The Board of Directors rejected unsolicited, non-binding acquisition proposals ranging from $4.00 to $4.25 per share, opting to continue as an independent public company despite the offers being at a significant premium to the current stock price.
Analysis · PETS · Trade & Services
PetMed Express reported a substantial full-year net loss of $57.3 million and negative Adjusted EBITDA, driven by a large $26.7 million goodwill impairment. While the fourth quarter showed some sequential improvement and a net loss of $(0.19) per share that reportedly beat analyst expectations, the overall financial health remains severely challenged. Critically, the Board rejected unsolicited acquisition proposals at a significant premium (nearly double the current stock price), opting to continue as an independent entity. This decision signals management's confidence in a turnaround but removes a potential near-term exit for shareholders at a much higher valuation, introducing considerable risk given the company's current financial distress.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PETS was trading at $2.12 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $45.6M. The 52-week trading range was $1.57 to $4.32. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.